Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer

Benzer Materyaller

• Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
  Yazar:: Patil, Tejas, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
  Yazar:: Patil, Tejas, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Erlotinib response in a NSCLC patient with a novel compound G719D+L861R mutation in EGFR
  Yazar:: Berge, Eamon M, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
  Yazar:: Yoshikawa, D, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
  Yazar:: Kurtis D Davies, ve diğerleri
  Baskı/Yayın Bilgisi: (2013-01-01)